2024
US Clinical Practice Experience with Eculizumab in Myasthenia Gravis: Acute Clinical Events and Healthcare Resource Utilization
Nowak R, Habib A, Klink A, Muppidi S, Parthan A, Sader S, Balanean A, Gajra A, Howard J. US Clinical Practice Experience with Eculizumab in Myasthenia Gravis: Acute Clinical Events and Healthcare Resource Utilization. Drugs - Real World Outcomes 2024, 11: 593-601. PMID: 39470958, PMCID: PMC11589080, DOI: 10.1007/s40801-024-00457-8.Peer-Reviewed Original ResearchHealthcare resource utilizationAssociated healthcare resource utilizationRescue therapy useEculizumab treatmentMyasthenia gravisMG exacerbationEculizumab initiationTherapy useMethodsA retrospective chart reviewTerminal complement inhibitor eculizumabRetrospective chart review analysisRates of healthcare resource utilizationComplement inhibitor eculizumabGeneralized myasthenia gravisRetrospective chart reviewChart review analysisTreatment of patientsUS adultsEculizumab therapyAcute clinical eventsMG crisisRescue therapyChart reviewEculizumabTherapy administration
2016
Eculizumab Therapy for Chronic Antibody-Mediated Injury in Kidney Transplant Recipients: A Pilot Randomized Controlled Trial
Kulkarni S, Kirkiles-Smith N, Deng YH, Formica RN, Moeckel G, Broecker V, Bow L, Tomlin R, Pober JS. Eculizumab Therapy for Chronic Antibody-Mediated Injury in Kidney Transplant Recipients: A Pilot Randomized Controlled Trial. American Journal Of Transplantation 2016, 17: 682-691. PMID: 27501352, DOI: 10.1111/ajt.14001.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAntibodies, Monoclonal, HumanizedChronic DiseaseComplement C5Complement Inactivating AgentsEarly Intervention, EducationalFemaleFollow-Up StudiesGlomerular Filtration RateGraft RejectionGraft SurvivalHumansIsoantibodiesKidney Failure, ChronicKidney Function TestsKidney TransplantationLiving DonorsMaleMiddle AgedPilot ProjectsPrognosisRisk FactorsTissue DonorsTransplant RecipientsYoung AdultConceptsDe novo donor-specific antibodiesComplement inhibitionTreatment groupsNovo donor-specific antibodiesAntibody-Mediated InjuryC1q-positive patientsDonor-specific antibodiesKidney transplant recipientsPrimary end pointEndothelial cell injuryMo of observationEculizumab therapyEculizumab treatmentHumoral injuryTransplant recipientsKidney transplantRenal functionKidney functionChronic settingEGFR trajectoriesTreatment periodCell injuryPatientsEnd pointPercentage change
2014
Eculizumab Therapy for Chronic Antibody-Mediated Injury in Kidney Transplantation: An Interim Assessment.
Kulkarni S, Nancy K, Formica R, Moeckel G, Pober J. Eculizumab Therapy for Chronic Antibody-Mediated Injury in Kidney Transplantation: An Interim Assessment. Transplantation 2014, 98: 79. DOI: 10.1097/00007890-201407151-00247.Peer-Reviewed Original Research
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply